Pharmacokinetics of Piperacillin/Tazobactam in Patients Treated by Continuous Renal Replacement Therapy (PTCRRT)
Diffusive and Convective Clearance
Piperacillin Tazocilline Concentrations (Cmin)
|Study Design:||Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Pharmacokinetics of Piperacillin and Tazobactam in Anuric Septic Patients Treated by Continuous Veno Venous Hemodiafiltration|
- Serum levels of both piperacillin and tazobactam (Cmin) during 2 daus [ Time Frame: 2 days ] [ Designated as safety issue: No ]
- Body clearance [ Time Frame: 2 days ] [ Designated as safety issue: No ]
|Study Start Date:||June 2008|
|Study Completion Date:||August 2012|
|Primary Completion Date:||August 2012 (Final data collection date for primary outcome measure)|
piperacillin 4 g and tazobactam 500 mg during 30 min IV infusion every 8h during 2 consecutive days
Other Name: TazocillineProcedure: Pharmacokinetic
The pharmacokinetics of piperacillin/tazobactam will be evaluated in twenty septic patients with renal failure undergoing continuous veno-venous hemodiafiltration. This is a prospective study.
Continuous replacement therapy has a continuous effect on drug elimination which could compromise effective antibiotic treatment.
Patients will receive a standard course of pip/tazo 4g intravenously 8 hourly administrated immediately when CVVHDF will be started.
Blood samples will be collected at 30mn, 2h, 4h, 6h, 8h, 16h, 24h for the first and the second day.
We will measure plasma piperacillin/tazobactam concentration and compare them to MICs for the whole dosing interval.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00703144
|Service de Néphrologie|
|Toulouse, France, 31059|
|Principal Investigator:||LAVAYSSIERE Laurence, MD||University Hospital, Toulouse|